Skanska signs additional contract for biotechnology facility in Charlottesville, USA, for USD 66M, about SEK 690M
Skanska signs additional contract for biotechnology facility in Charlottesville, USA, for USD 66M, about SEK 690M |
| [20-May-2025] |
STOCKHOLM, May 20, 2025 /PRNewswire/ -- Skanska has signed an additional contract with the University of Virginia for the construction of the Paul and Diane Manning Institute of Biotechnology at Fontaine Research Park in Charlottesville, Virginia. The additional contract is worth USD 66M, about SEK 690M, which will be included in the US order bookings for the second quarter of 2025. Upon completion, the five-story, approximately 33,000 square meter (354,000-square-foot) Paul and Diane Manning Institute of Biotechnology at the University of Virginia will be a state-of-the-art facility to house the first-of-its-kind translational research program in the Commonwealth. The building will include modular, multi-use laboratory space and support space, expanded research facilities, core facilities and an area for 100-150 researchers and partnering biotechnology companies to foster collaboration on the frontlines of science and technology. Construction began in December 2023 and is expected to be completed in the fourth quarter of 2027. For further information please contact: Ashley Jeffery, Communications Manager, USA Building, tel +1 813 459 3682 Andreas Joons, Press Officer, Skanska Group, tel +46 76 870 75 51 Direct line for media, tel +46 (0)10 448 88 99 This and previous releases can also be found at www.skanska.com. This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Skanska | ||||||
Company Codes: Bloomberg:SKAB@SS, ISIN:SE0000113250, RICS:SKAB.ST, Stockholm:SKAB, OTC-PINK:SKBSY |
View original content:
